Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.
Typical daily range: 200–600 mcg once daily (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Week | Daily Dose (mcg) | Units (per injection) (mL) |
Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 10 for better accuracy. Dosing is extrapolated from preclinical models; human clinical validation remains limited.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
8 weeks ≈ 6 vials (25.2 mg used)
12 weeks ≈ 9 vials (42 mg used)
16 weeks ≈ 12 vials (58.8 mg used)
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water: Use ~3.0 mL per vial for reconstitution.
8 weeks (6 vials): 18 mL
12 weeks (9 vials): 27 mL
16 weeks (12 vials): 36 mL
Alcohol Pads: One for the vial stopper + one for the injection site each day.
Per week: 14 pads (2/day)
8 weeks: 112 pads
12 weeks: 168 pads
16 weeks: 224 pads
Protocol Overview
Concise summary of the once-daily regimen.
Goal: Support tissue-healing and recovery processes based on preclinical evidence.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 200–600 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
Start: 200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated.
Target: 400–600 mcg daily by Weeks 5–8+.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.
How This Works
BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data are not yet available.
Potential Benefits & Side Effects
Observations from preclinical and early clinical literature.
Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
Phase I safety studies report good tolerability with no serious adverse events at tested doses.
Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
Long-term human safety and efficacy remain under investigation.
Lifestyle Factors
Complementary strategies for best outcomes.
Support recovery with adequate protein intake and micronutrient-rich foods.
Balance activity and rest to allow tissue adaptation without overuse.
Prioritize sleep and stress management to enhance natural healing processes.
Consult qualified healthcare providers for injury-specific rehabilitation guidance.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Discard used syringes immediately in a sharps container per WHO guidelines.